{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:14:52Z","timestamp":1768680892511,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1124\/jpet.120.000014","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T23:07:31Z","timestamp":1593126451000},"page":"392-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity"],"prefix":"10.1016","volume":"374","author":[{"given":"Michael D.","family":"Raleigh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Accetturo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-0184","authenticated-orcid":false,"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000014_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2006.01.047","article-title":"A novel bivalent morphine\/heroin vaccine that prevents relapse to heroin addiction in rodents","volume":"24","author":"Anton","year":"2006","journal-title":"Vaccine"},{"key":"10.1124\/jpet.120.000014_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.exppara.2018.04.015","article-title":"Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection","volume":"189","author":"Azizi","year":"2018","journal-title":"Exp Parasitol"},{"key":"10.1124\/jpet.120.000014_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.npp.1300274","article-title":"Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats","volume":"28","author":"Bartus","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.120.000014_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drugalcdep.2011.10.018","article-title":"Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course","volume":"123","author":"Bigelow","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.120.000014_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ajad.12711","article-title":"Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies","volume":"27","author":"Bisaga","year":"2018","journal-title":"Am J Addict"},{"key":"10.1124\/jpet.120.000014_bib6","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1124\/jpet.120.000014_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jps.20327","article-title":"Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833","volume":"94","author":"Bostr\u00f6m","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.120.000014_bib8","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.106.009746","article-title":"In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics\/pharmacodynamics","volume":"34","author":"Bostr\u00f6m","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000014_bib9","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1073\/pnas.98.4.1988","article-title":"A second-generation vaccine protects against the psychoactive effects of cocaine","volume":"98","author":"Carrera","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.000014_bib10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.intimp.2011.07.009","article-title":"Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy","volume":"11","author":"Cornish","year":"2011","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/jpet.120.000014_bib11","doi-asserted-by":"crossref","first-page":"e2547","DOI":"10.1371\/journal.pone.0002547","article-title":"A vaccine against nicotine for smoking cessation: a randomized controlled trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000014_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/08897077.2011.609438","article-title":"A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers","volume":"33","author":"Coviello","year":"2012","journal-title":"Subst Abus"},{"key":"10.1124\/jpet.120.000014_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.pbb.2008.02.006","article-title":"Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone","volume":"89","author":"Dean","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.120.000014_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2011.06.023","article-title":"Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial","volume":"120","author":"DeFulio","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.120.000014_bib15","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/appi.ajp.2010.10020260","article-title":"Prescription pain medication dependence","volume":"168","author":"Dodrill","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.120.000014_bib16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2010.317","article-title":"Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic","volume":"89","author":"Hatsukami","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000014_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1248\/bpb1978.5.521","article-title":"Determination of oxycodone metabolites in urines and feces of several mammalian species","volume":"5","author":"Ishida","year":"1982","journal-title":"J Pharmacobiodyn"},{"key":"10.1124\/jpet.120.000014_bib18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.120.000014_bib19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2018.2844","article-title":"Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016","volume":"319","author":"Jones","year":"2018","journal-title":"JAMA"},{"key":"10.1124\/jpet.120.000014_bib20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1360-0443.2012.03910.x","article-title":"Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use","volume":"107","author":"Kelty","year":"2012","journal-title":"Addiction"},{"key":"10.1124\/jpet.120.000014_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.exppara.2016.01.001","article-title":"Mixture of Alum--Naloxone and Alum--Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB \/c mice","volume":"162","author":"Khorshidvand","year":"2016","journal-title":"Exp Parasitol"},{"key":"10.1124\/jpet.120.000014_bib22","first-page":"1","article-title":"Long-acting injectable naltrexone for the management of patients with opioid dependence","volume":"5","author":"Kjome","year":"2011","journal-title":"Subst Abuse"},{"key":"10.1124\/jpet.120.000014_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"key":"10.1124\/jpet.120.000014_bib24","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1124\/jpet.120.000014_bib25","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.4049\/jimmunol.1500385","article-title":"The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse","volume":"194","author":"Laudenbach","year":"2015","journal-title":"J Immunol"},{"key":"10.1124\/jpet.120.000014_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pbb.2005.08.008","article-title":"Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats","volume":"82","author":"Leri","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.120.000014_bib27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1471-4159.2011.07502.x","article-title":"A morphine\/heroin vaccine with new hapten design attenuates behavioral effects in rats","volume":"119","author":"Li","year":"2011","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.120.000014_bib28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.coi.2011.08.003","article-title":"IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation","volume":"23","author":"Liao","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1124\/jpet.120.000014_bib29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial","volume":"66","author":"Martell","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.120.000014_bib30","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.bmcl.2014.05.033","article-title":"Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues","volume":"24","author":"Metcalf","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.120.000014_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0376-8716(97)01348-3","article-title":"Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts","volume":"45","author":"Miotto","year":"1997","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.120.000014_bib32","first-page":"311","article-title":"Evaluation of alum-naltrexone adjuvant activity, on efficacy of anti-leishmania immunization with autoclaved leishmania major (MRHO\/IR\/75\/ER) antigens in BALB\/C mice","volume":"9","author":"Mohammadzadeh Hajipirloo","year":"2014","journal-title":"Iran J Parasitol"},{"key":"10.1124\/jpet.120.000014_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jps.21807","article-title":"Drug-drug interaction between oxycodone and adjuvant analgesics in blood-brain barrier transport and antinociceptive effect","volume":"99","author":"Nakazawa","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.120.000014_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","article-title":"Prophylactic vaccination protects against the development of oxycodone self-administration","volume":"138","author":"Nguyen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.120.000014_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.pbb.2013.06.010","article-title":"Oxycodone-induced conditioned place preference and sensitization of locomotor activity in adolescent and adult mice","volume":"110","author":"Niikura","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.120.000014_bib36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): who will respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"J Addict Med"},{"key":"10.1124\/jpet.120.000014_bib37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1124\/dmd.108.022087","article-title":"Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone","volume":"36","author":"Okura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000014_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000014_bib39","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.000014_bib40","doi-asserted-by":"crossref","first-page":"e101807","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000014_bib41","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"key":"10.1124\/jpet.120.000014_bib42","doi-asserted-by":"crossref","first-page":"e96547","DOI":"10.1371\/journal.pone.0096547","article-title":"Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000014_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1601-183X.2008.00388.x","article-title":"Behavioral characterization of mice lacking GIRK\/Kir3 channel subunits","volume":"7","author":"Pravetoni","year":"2008","journal-title":"Genes Brain Behav"},{"key":"10.1124\/jpet.120.000014_bib44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000014_bib45","doi-asserted-by":"crossref","first-page":"e0184876","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.000014_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000014_bib47","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/21645515.2018.1558697","article-title":"Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders","volume":"15","author":"Robinson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1124\/jpet.120.000014_bib48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/sj.bjp.0701138","article-title":"Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study","volume":"121","author":"Sacerdote","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.000014_bib49","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1002\/jps.22567","article-title":"Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo","volume":"100","author":"Sadiq","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.120.000014_bib50","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1021\/jm200461m","article-title":"A vaccine strategy that induces protective immunity against heroin","volume":"54","author":"Stowe","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.120.000014_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5152\/tpd.2013.22","article-title":"A novel adjuvant, mixture of Alum and naltrexone, elicits humoral immune responses for excreted\/secreted antigens of Toxoplasma gondii tachyzoites vaccine in Balb\/c murine model","volume":"37","author":"Tappeh","year":"2013","journal-title":"Turkiye Parazitol Derg"},{"key":"10.1124\/jpet.120.000014_bib52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.000014_bib53","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/npp.2011.200","article-title":"Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects","volume":"37","author":"Wee","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.120.000014_bib54","unstructured":"WHO (2018) Information sheet on opioid overdose."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:32:49Z","timestamp":1739964769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0022356524258286"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000014","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}